Supplementary Figure 4. CD8⁺ T cells infiltration or NKG2A expression alone could not predict prognosis of ccRCC patients treated with Nivolumab or Everolimus in CheckMate cohort. (A-B) OS of patients treated with Nivolumab based on NKG2A expression (A) or CD8⁺ T cells infiltration (B). (C-D) OS of patients treated with Everolimus based on NKG2A expression (C) or CD8⁺ T cells infiltration (D).